Background: Factors affecting serum PSA levels in men are clinically important, but, apart from effects mediated through the androgen receptor, poorly understood.
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Introduction
Each year around 900.000 men are diagnosed with prostate cancer [1] . Most of them are discovered due to raised serum levels of prostate specific antigen (PSA). The PSA gene, KLK3, and the related KLK2 are androgen regulated and highly expressed in the epithelial cells of the prostate. The levels of PSA in the prostate is reported to be over 100 times higher than KLK2, while PSA transcripts are only twice as abundant as KLK2 [2] [3] [4] . The discrepancy in protein-to-transcript ratios has been ascribed to a lower stability of KLK2 [5, 6] . When the PSA test was introduced in clinical practice in the midnineties it resulted in an increased prostate cancer incidence, notably without the equivalent decrease in mortality rates. In fact, over detection was estimated to be approximately 50% in the European Randomized Study of Screening for Prostate Cancer [7] , leading to overtreatment and decreased quality of life for many men. Thus, there is a need to improve the accuracy of the PSA test both in detection and subsequent prognostication of prostate cancer. This might be achieved by learning more about factors affecting PSA synthesis and secretion.
MicroRNAs (miRNAs) are short regulatory non-coding RNAs reported to be altered in all malignant tissues investigated, including the prostate [8] . Typically, miRNAs bind the 3'UTR of its target mRNA, causing reduction of protein expression. However, there are reports showing that miRNAs can also lead to increased protein expression [9, 10] .
In this study, we investigate if miRNAs regulate the expression of PSA and KLK2 using 3'UTR reporter assays and gain-of-function screening with a miRNA library. A miRNA, mir-183, identified in the screen is demonstrated to directly target the 3'UTR of PSA and to co-variate with serum PSA levels in a patient cohorts.
Material and methods

In vitro manipulations
Prostate cancer cell lines DU145, PC3, 22Rv1, LNCaP clone FGC (ATCC), LNCaP (from DSMZ for the screening), LAPC-4 and LNCaP-ARhi were cultured according to the manufacturer's recommendations. RevertAid cDNA synthesis kit (Thermo Scientific, Wilmington, DE) was used for cDNA production and AR, KLK2, KLK3 and GAPDH transcripts were quantified by TaqMan qPCR (Life Technologies, primersHs00171172_m1, Hs00428384_g1, Hs02576345_m1 and Hs02758991_g1). free PSA (fPSA) and total PSA (tPSA) were measured with DELFIA Prostatus™ PSAF/T (Perkin-Elmer Life Sciences, Turku, Finland) [11] . KLK2 was measured as described by Vaisanen et al. [13] Transfections of miRNAs and 600 pmole/ml of LNA target site blockers (TSB) (Exiqon) designed to bind the predicted miR-183 target site in the 3'UTR (TSB-A) and a random site (TSB-B) of PSA, and a site in MET (TSB-C) (Suppl. Fig.1 ), were done using Lipofectin (Life Technologies) and f and tPSA measured after 72 hours. Western blots were probed with antibodies against PSA (in house rabbit polyclonal [12] ), AR (N-20, SC-816, Santa Cruz Biotechnology, TX), GAPDH (MAB374, Chemicon, Temecula, CA) and HRP coupled polyclonal secondary antibodies (mouse or rabbit, Dako). All experiments were performed in triplicate.
High-throughput screening
LNCaP and LAPC-4 were reverse transfected in duplicate with 20 µmol/mL Pre-miR miRNA Precursor library v2 (Ambion, Austin, TX, 319 molecules) or miRIDIAN microRNA Mimic Libraries v10.1 (Dharmacon, Lafayette, CO, 819 molecules) as described previously [13] . PSA expression was detected at 48 and 72 hours, by staining RRPA slides with PSA antibody (#A0562, Dako Cytomation, Denmark) overnight. The results were normalized using the Loess method and log 2 transformed, after which RankProd was used to identify regulating miRNAs [14] .
Patients and miRNA quantification
Cohort 1 (49 prostate cancer and 25 without) obtained by transurethral resection of the prostate has been described previously [15] and in Suppl. Tab. 1. Cohort 2 consists of FFPE cores obtained from radical prostatectomies from 122 men with prostate adenocarcinoma collected at Malmö University hospital 1999 -2002. Selected core from 28 patients did not contain cancer cells and were discarded; the remaining 94 specimens are described in Suppl. Tab. 1. Ethical approvals have been obtained from the Regional ethical review board, Lund, Sweden and we adhere to the Helsinki Declaration.
RNA was extracted from the prostatic tissue in cohort 1 and 2 and miR-183 quantified as previously described [16, 17] . The miR-183 level was normalised against the geometrical mean of RNU47, RNU48 and RNU66, the selection based on a previous screen [17] . These non-coding RNAs also served as control for the RNA integrity. For external validation of our results we analysed a data set 
Functional assays
The 3'UTRs of KLK3 (637 nt) and KLK2 (672 nt) were cloned into pMIR-REPORTER (Life Technologies) and the identity of the inserts confirmed by DNA sequencing. 22Rv1 and LNCaP cells were transfected as described above, and a pRL Renilla firefly construct served as normaliser. Luciferase activity was measured 72 h after transfection with Dual-Glo Luciferase Assay System (Promega, Madison, WI) according to the manufacturer's instructions, and measured in triplicate on a Wallac 1420 Victor2 TM (Perkin Elmer). The Sulforhodamine B (SRB) colorimetric assay was performed as described previously [19] .
Statistical analysis
Student's t test was used for the in vitro experiments and the Rank Product method was used to evaluate the RPPA. Spearman's rank was used to compare PSA to miR-183 expression, Cuzick's trend test was used to analyse miR-183 expression and WHO status, and overall survival was analyzed using Kaplan-Meier curves, and statistical significance was assessed with the Log-Rank method.
Levels of statistically significance were set at p < 0.05.
Results
PSA is post transcriptionally regulated
We could verify and expand earlier findings that the protein/transcript ratios were drastically higher for PSA than KLK2 in several cell lines ( Fig. 1A) . To test whether translational blocking by miRNAs decrease protein levels, the 3'UTRs of PSA and KLK2 were cloned to reporter vectors and introduced into LNCaP cells. Surprisingly, the introduction of KLK2 3'UTR had no effect, whereas the PSA 3'UTR significantly increased luciferase levels (p=0.002, Student's t test, Fig. 1B ). To determine if the increased translation was due to miRNAs, the cells were treated with siRNAs directed towards Dicer, as all miRNAs (except miR-451) undergo Dicer-dependent maturation. The increased luciferase levels caused by the PSA 3'UTR was significantly decreased when adding siRNAs against Dicer, implicating post-transcriptional regulation by miRNAs ( Fig 1C) . 
Systematic analyses of miRNAs regulating PSA levels
High-throughput RPPA miRNA screens was conducted to identify individual miRNAs influencing the levels of PSA in two androgen dependent prostate cancer cell lines at two time points. The cells were transfected with two miRNA mimic libraries containing a total of 1129 molecules. The result is consistent over time in LNCaP cells while more varying in the LAPC-4, as expected as the PSA levels are close to the detection limit in the latter. The subsequent analyses were hence based on the results from the LNCaP cell line. We identified a total of 62 unique miRNAs having effect on PSA expression; 32 upregulated and 30 downregulated PSA levels (FDR p-value < 0.05; Fig. 2 , Supp. Table   2 and 3). None of the miRNAs increasing PSA had been identified to target AR in an earlier RPPA screen performed in the same setting [20] . However, among the miRNAs decreasing PSA levels, 40%
had been identified to target AR, indicating that the reduction in PSA levels could be secondary to an effect mediated by the AR regulation.
miR-183 increase mRNA and protein levels of PSA
Three miRNAs increasing PSA levels and predicted to target KLK3; miR-183, predicted to target the 3'UTR and upregulated in prostate cancer patients [17] , miR-650 predicted to target the CDS and promotes tumourigenicity in gastric cancer [21] and miR-423 predicted to target the promoter and increased in metastatic breast cancer patients [22] were selected for further validation. Both secreted and intracellular levels of tPSA and fPSA were increased in prostate cancer cells upon transfection with mimic-miR-183, mimic-miR-423, mimic-miR-650 compared to the scramble control ( Fig 3A-B and Suppl. Tab. 4). The effect was reversed when blocking miR-183 (tPSA p = 0.004, Fig. 3C and Suppl. Tab. 4), but not miR-423 nor -650 (results not shown),indicating that the latter two does not regulate PSA levels in this setting. Based on this, only miR-183 was selected for further investigation. In Western blotting miR-183 significantly upregulated PSA in 22Rv1 and LNCaP cells (p = 0.04 and 0.0002 respectively, Fig 3D) . Further, miR-183 does not change the proteolytic activity of PSA (Suppl. Fig. 2 ), also supported by the unchanged f/tPSA ratio (Suppl. Table 4 ). Ectopic expression of miR-183 also increased the transcript levels of PSA, (p = 0.01 in 22Rv1 and p = 0.0001 in LNCaP, Fig. 3E ). This effect is not mediated through the AR, as miR-183 does not affect AR transcript nor protein levels (Suppl. Fig. 3 ), confirming that miR-183 act though post-transcriptional mechanisms. A luciferase reporter assay verified that miR-183 bind directly to the 3'UTR of PSA in both LNCaP and 22Rv1 cells ( Fig.4A and B ). Next, a TSB was designed to prevent miR-183 to access the site predicted using the algorithm RNA22 (TSB-A). The increased levels of PSA induced by miR-183 was abolished 7 when co-transfecting with TSB-A (tPSA, p = 0.02, Fig. 4C , fPSA p= 0.01, Suppl. Fig. 4 ). Introduction of the TSB-A on its own did not have effect on the PSA levels compared to the control TSBs or nontransfected cells indicating that the effect is specific. In the KLK2 3'UTR the seeding site of the miR-183 binding is mutated, hence it is possible that miR-183 binding to this site can explain at least part of PSAs higher protein/transcript ratio.
Correlation to serum PSA and clinical parameters
Next, we set out to investigate miR-183 regulation of PSA in clinical material. In cohort 1, the miR-183 expression level in the prostate was positively correlated to patient serum PSA level (Spearman rho = 0.35, p = 0.005, Fig.5A ). It is noteworthy that in this cohort, two men with untreated prostate cancer have miR-183 levels below the median and PSA levels less than 3.0 ng/ml and hence could have been missed in a PSA screen. To support the correlation found in cohort 1, an external dataset constituting a cohort of 138 prostate specimens was analysed. The analysis of this dataset showed a positive correlation between miR-183 and the PSA encoding transcript (Spearman rho = 0.2, p = 0.02, Fig. 5B) [18]. Further, there is no correlation between miR-183 and AR in the patient cohort 1 supporting the in vitro findings that miR-183 is acting by post-transcriptional regulation. The expression of miR-183 is significantly increased with WHO grade (p = 0.03, Cuzick's trend test, Fig. 5C ). In line with this miR-183 induced cell growth in LNCaP, PC3, and DU145 (p = 0.046, 0.00085, and 0.0016, Fig. 6 ).
Conversely, inhibiting endogenous miR-183 decreased cell growth in all cell lines ( Fig. 6E-H) . We have identified one of the targets of miR-183 contributing to this phenotype: transient expression of miR-183 decrease FOXO1 as shown by western blot in LNCaP (p = 0.006, Suppl. Fig 5) . The ability of miR-183 to predict clinical progression, defined as biochemical recurrence, prostate cancer related death or adjuvant therapy after diagnosis was further analysed in the larger cohort 2. Patients were divided into two groups according to expression of miR-183 and clinical progression analysed by Kaplan-Meyer curves. We found a hazard ratio of 2.9 for earlier clinical recurrence in patients with high miR-183. For patients with low to medium miR-183 levels, less than 50% experienced clinical progression, whereas the median time to clinical progression for patients with high levels was 11.15 years (p = 0.02, Log-Rank, Fig. 5D ). As comprehensive pre-treatment PSA data was not available, the independence to PSA could not conclusively be investigated.
Discussion
In this study we address the post-transcriptional regulation of PSA by miRNA. We show a 3'UTR dependent upregulation of PSA, mediated by miRNA, as demonstrated by decreased reporter activity upon siRNA targeting of Dicer. In a systematic gain-of-function screening 62 individual miRNAs were identified to regulate PSA levels. Of these, miR-183 was further studied, and confirmed to increase PSA levels, target the 3'UTR and to correlate to serum PSA. To our knowledge, this is the first report of miRNAs directly regulating PSA levels. As PSA is currently used in clinical practice throughout the world for detection and monitoring of prostate cancer, it is of high importance to enhance the understanding of the mechanisms regulating this molecule, as e.g. men with prostate cancer and low miR-183 levels might go undetected in a PSA-based screening.
The regulatory effect of miR-183 on PSA is mediated through binding a specific site in the 3'UTR, but the exact mechanism, whether it pertains to mRNA half-life or translation efficiency, remains to be elucidated. It is of interest to note that the effect on PSA mRNA level is less pronounced than the effect on protein level, and the correlation between miR-183 and PSA encoding transcript is also weaker than to the protein. These findings indicate that possibly both mechnisms are affected.
Several miRNAs has been reported to bind the 3'-UTRs causing increased translation their targets [9, 23, 24] , a mechanism that has been suggested is that the miRNA-Argonaute complex can recruit the RNA binding protein FXR1 to the mRNA and activate translation during cell cycle arrest. Previously, we and others have shown that miR-183 is upregulated in prostate cancer tumours [17, 25, 26] .
Here, we show that miR-183 levels significantly correlates with increasing WHO grade and that high levels correspond to earlier clinical progression, suggesting oncogenic properties and confirming earlier findings [26] . In line with this, we found that miR-183 increase cell growth in vitro, and we identified a potential mechanism through FOXO1 regulation, confirming earlier findings in endometrial cancer and Hodgkin lymphoma [27, 28] . It is possible that in addition to directly regulate PSA, miR-183 also indirectly increases the PSA levels by increasing the proliferation of the prostate cancer cells.
Not only is the intracellular PSA level regulated by miR-183, but also the secreted portion is affected, suggesting that miR-183 can influence serum PSA levels. Substantiating the functional data, we found a positive correlation between miR-183 and serum PSA levels in a prostate cancer cohort, something that is also confirmed in an earlier study [26] . In current clinical practice the level of tPSA is used to monitor prostate cancer, but decreased fPSA/tPSA has been proposed to be associated with more aggressive cancer [29] , therefore it is noteworthy that miR-183 does not change this ratio.
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Conclusions: To identify factors that influence the levels of PSA in serum and thus increase the accuracy of this test can lead to less unnecessary invasive diagnostic procedures and reduce over diagnosis. This study identifies miR-183 as a regulator of PSA levels in prostate cancer cells and in serum. As such, the individual's miR-183 levels might influence current prostate cancer detection and monitoring. and found that the transcript of KLK3 and miR-183 significantly correlates. C) In cohort 1, there is a significant trend of increasing miR-183 related to WHO grading. D) In cohort 2, constituting 94 men with adenocarcinoma, we find that clinical progression occurs earlier in patients with high miR-183 compared to low. In LNCaP, only miR-183 on its own upregulates the fPSA expression, but co-transfecting mimic-miR-183 with TSB-A rescue this effect. All results are normalised to a co-transfected Renilla firefly construct to compensate for variation in transfection efficiency and cell number. 
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